醫(yī)療特長(zhǎng)：
從事消化科臨床工作三十余年，對(duì)消化系統(tǒng)常見(jiàn)疾?。ò晕秆?、胃食管返流病、消化性潰瘍,、慢性肝病,、功能性胃腸病等）的診斷與治療有著豐富的臨床經(jīng)驗(yàn)；熟練掌握消化內(nèi)鏡技術(shù),。尤其擅長(zhǎng)腸道潰瘍,、腸道炎癥性疾病，如潰瘍性結(jié)腸炎,、克羅恩病的診斷及治療。
中山醫(yī)科大學(xué)（現(xiàn)中山大學(xué)醫(yī)學(xué)院）臨床醫(yī)學(xué)學(xué)士,、中山大學(xué)附屬第一醫(yī)院消化科醫(yī)學(xué)博士,、美國(guó)UCLA教學(xué)醫(yī)院Cedar-Sinai 醫(yī)療中心博士后、美國(guó)西南大學(xué)醫(yī)學(xué)院炎癥性腸病中心訪問(wèn)學(xué)者,。
社會(huì)兼職：
中華醫(yī)學(xué)會(huì)消化病學(xué)分會(huì)炎癥性腸病學(xué)組副組長(zhǎng)
中國(guó)炎癥性腸病診治質(zhì)控評(píng)估中心秘書長(zhǎng)
亞洲炎癥性腸病協(xié)會(huì)(AOCC) 臨床研究學(xué)組主任
廣東省醫(yī)師協(xié)會(huì)消化內(nèi)鏡分會(huì)副主任委員
在國(guó)內(nèi)外學(xué)術(shù)期刊共發(fā)表學(xué)術(shù)論文近百篇,，參編專著8部。多次在大型國(guó)際國(guó)內(nèi)學(xué)術(shù)會(huì)議上進(jìn)行主題演講,。
代表性論著：
1. Predicting Factors of Long-term Outcome of Gastrointestinal Behcet’s Disease: A Chinese Retrospective Study. Clin Ther. 2024 Jan 30:S0149-2918(24)00005-5. doi: 10.1016/j.clinthera.2023.12.012.
2. Role of Colchicine in Different Clinical Phenotypes of Behcet Disease. Clin Ther. 2023 Feb;45(2):162-176. doi: 10.1016/j.clinthera.2023.01.004. Epub 2023 Feb 1. Erratum in: Clin Ther. 2023 Sep;45(9):923. PMID: 36732153.
3. Mucosal Healing and Quality of Life in Therapeutic Goals of Ulcerative Colitis: Occurrence and Related Factors of Functional Bowel Disorders. Therap Adv Gastroenterol 2022:17562848221092597.doi: 10.1177/17562848221092597
4. Multi-omics Analysis of Western-style Diet Increased Susceptibility to Experimental Inflammatory Bowel Disease. J Inflamm Res 2022 Apr 21;15:2523-2537
5. IBD合并風(fēng)濕免疫病診治策略(綜述),。中華炎性腸病雜志 2021
6. 狹窄型克羅恩病的診斷與治療進(jìn)展（綜述）。中國(guó)醫(yī)學(xué)前沿雜志2021
7. Thalidomide induces clinical remission and mucosal healing in adults with active Crohn's disease: a prospective open-label study. CYP2C19 polymorphism has no correlation with the efficacy and safety of thalidomide for the treatment of immune-related bowel disease. J Dig Dis. 2020 Feb;21(2):98-103.
8. Epstein-Barr virus status on clinicopathologic characteristics and clinical outcomes in ulcerative colitis：a study on high incidence area of the viral infection. Therapeutic Advances in Gastroenterology 2020
9. Which Long Noncoding RNAs and Circular RNAs Contribute to Inflammatory Bowel Disease?（綜述） Cell death and disease.2020 Jun 15;11(6):456
10. 沙利度胺治療難治性克羅恩病的長(zhǎng)期療效及安全性分析. 中華內(nèi)科雜志, 2020, 59 (6).
11. Development and validation of a novel diagnostic nomogram to differentiate between Intestinal tuberculosis and Crohn’s Disease: A 6-year prospective multi-center study. Am J Gastroenterol 2019 Mar;114(3):490-499
12. Thalidomide induces clinical remission and mucosal healing in adults with active Crohn's disease: a prospective open-label study. Therap Adv Gastroenterol. 2017 May;10(5):397-406
13. The value of empiric anti-tuberculosis therapy in the differential diagnosis between intestinal tuberculosis and Crohn’s disease in China. Int J Clin Exp Med. 2016;9(6):9278-85.( IF: 1.277)
14. Prevalence and influences of hepatitis B virus infection on inflammatory bowel disease: a retrospective study in southern China. Int J Clin Exp Med. 2015;8(5):8078-85.( IF: 1.277)
15. 難治性克羅恩病的臨床特征及影響因素分析. 中華醫(yī)學(xué)雜志 2014,；94(38): 2982-2987
16. 甲氨蝶呤治療難治性克羅恩病的療效及安全性分析. 中華內(nèi)科雜志. 2014; 53(3): 188-192
17. Activation of PI3K/Akt/mTOR signaling pathway triggered by PTEN downregulation in the pathogenesis of Crohn's disease. J Dig Dis. 2013; 14(12): 662-669.
18. PCR法檢測(cè)分枝桿菌DNA在鑒別克羅恩病與腸結(jié)核中的價(jià)值. 中國(guó)病理生理雜志. 2013; 29 (1): 188-192
19. 回結(jié)腸克羅恩病與腸結(jié)核臨床及內(nèi)鏡特征比較. 中華消化內(nèi)鏡雜志. 2012; 26(6): 48-52
20. 沙利度胺治療克羅恩病的研究進(jìn)展（綜述）. 胃腸病學(xué) 2012; 9: 570-572
21. 專家筆談：克羅恩病的診斷與鑒別診斷. 現(xiàn)代消化及介入診療 2010; 15(4): 236-240
22. 專家筆談：炎癥性腸病的內(nèi)科治療. 實(shí)用醫(yī)學(xué)雜志 2003;5(19):453-455
